- Previous Close
8.36 - Open
8.40 - Bid 8.16 x 700
- Ask 8.21 x 100
- Day's Range
8.11 - 8.44 - 52 Week Range
4.97 - 16.75 - Volume
3,587,589 - Avg. Volume
5,612,783 - Market Cap (intraday)
2.204B - Beta (5Y Monthly) 0.82
- PE Ratio (TTM)
-- - EPS (TTM)
-1.63 - Earnings Date Aug 6, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.57
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
www.recursion.comRecent News: RXRX
View More
Performance Overview: RXRX
Trailing total returns as of 7/15/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RXRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RXRX
View MoreValuation Measures
Market Cap
2.24B
Enterprise Value
2.00B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
40.47
Price/Book (mrq)
5.59
Enterprise Value/Revenue
44.19
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-39.82%
Return on Equity (ttm)
-85.19%
Revenue (ttm)
46.23M
Net Income Avi to Common (ttm)
-354.11M
Diluted EPS (ttm)
-1.63
Balance Sheet and Cash Flow
Total Cash (mrq)
296.33M
Total Debt/Equity (mrq)
12.71%
Levered Free Cash Flow (ttm)
-208.61M
Research Analysis: RXRX
View MoreCompany Insights: RXRX
RXRX does not have Company Insights